Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-clear Renal Cell Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 0 results

Early research (Phase 1)Looking for participantsNCT05176483
What this trial is testing

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Who this might be right for
Renal Cell Carcinoma (RCC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)Urothelial Carcinoma (UC)+8 more
Exelixis 1,394
Testing effectiveness (Phase 2)Ended earlyNCT00788125
What this trial is testing

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

Who this might be right for
Brain and Central Nervous System TumorsChildhood Germ Cell TumorExtragonadal Germ Cell Tumor+8 more
City of Hope Medical Center 7
Testing effectiveness (Phase 2)Active Not RecruitingNCT05808608
What this trial is testing

AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma

Who this might be right for
Renal Cell CarcinomaFirst-line TreatmentNon Clear Cell Renal Cell Carcinoma+1 more
Hao Zeng 37
Testing effectiveness (Phase 2)Study completedNCT00866320
What this trial is testing

Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab

Who this might be right for
Kidney Cancer
Case Comprehensive Cancer Center 49
Early research (Phase 1)Study completedNCT02315066
What this trial is testing

Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566

Who this might be right for
Neoplasms
Pfizer 174
Not applicableWithdrawnNCT00499291
What this trial is testing

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors

Who this might be right for
Cancer
Eastern Cooperative Oncology Group
Early research (Phase 1)Ended earlyNCT02595918
What this trial is testing

Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery

Who this might be right for
Clear Cell Renal Cell CarcinomaMetastatic Renal Cell CarcinomaStage I Renal Cell Cancer AJCC v6 and v7+3 more
National Cancer Institute (NCI) 19
Testing effectiveness (Phase 2)Ended earlyNCT01582009
What this trial is testing

Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

Who this might be right for
Clear Cell Renal Cell CarcinomaRecurrent Renal Cell CancerStage III Renal Cell Cancer+1 more
Roswell Park Cancer Institute 26
Testing effectiveness (Phase 2)UnknownNCT04995016
What this trial is testing

Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma

Who this might be right for
Renal Cell CarcinomaClear Cell Renal Cell Carcinoma
Tianjin Medical University Second Hospital 18
Testing effectiveness (Phase 2)UnknownNCT03177239
What this trial is testing

Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)

Who this might be right for
Renal Cell CarcinomaPapillary Renal Cell Carcinoma Type 1Papillary Renal Cell Carcinoma Type 2+3 more
Australian and New Zealand Urogenital and Prostate Cancer Trials Group 85
Testing effectiveness (Phase 2)Study completedNCT00003657
What this trial is testing

High-dose ICE With Amifostine

Who this might be right for
Bladder CancerBrain and Central Nervous System TumorsCarcinoma of Unknown Primary+8 more
Dana-Farber Cancer Institute 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT03635892
What this trial is testing

Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

Who this might be right for
Advanced or Metastatic Non-clear Cell Renal Cell CarcinomaUnclassified Renal Cell CarcinomaPapillary Renal Cell Carcinoma+4 more
Memorial Sloan Kettering Cancer Center 60
Early research (Phase 1)Study completedNCT04148937
What this trial is testing

The CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

Who this might be right for
Advanced Cancer
Eli Lilly and Company 52
Testing effectiveness (Phase 2)Looking for participantsNCT05706129
What this trial is testing

Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Clear Cell Renal Cell Cancer (ccRCC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)+6 more
Lumara Bio Oncologics GmbH 270
Testing effectiveness (Phase 2)Looking for participantsNCT05768464
What this trial is testing

Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors

Who this might be right for
Non-clear Renal Cell Carcinoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 30
Early research (Phase 1)Study completedNCT02575222
What this trial is testing

Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma

Who this might be right for
Clear Cell Renal Cell Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 17
Testing effectiveness (Phase 2)Ended earlyNCT00491075
What this trial is testing

Pemetrexed Plus Gemcitabine in Renal Cell Cancer

Who this might be right for
Renal Cell Carcinoma
M.D. Anderson Cancer Center 16
Early research (Phase 1)Study completedNCT01672775
What this trial is testing

Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology

Who this might be right for
Carcinoma, Renal CellRenal Cell Carcinoma of Papillary HistologyRenal Cell Carcinoma With Clear Cell Histology+1 more
Agensys, Inc. 34